论文部分内容阅读
目的比较莫西沙星与哌拉西林舒巴坦钠治疗社区获得性肺炎的临床疗效。方法 2010年3月-2011年3月,98例社区获得性肺炎患者随机分为两组,A组49例采用莫西沙星治疗,B组49例采用哌拉西林舒巴坦钠治疗,比较观察两组的临床疗效以及主要症状、体征恢复情况。结果 A组的总有效率和细菌清除率明显高于B组(P<0.05)。A组咳嗽消失、体温恢复正常、血常规恢复正常和胸部影像明显吸收时间明显短于B组(P<0.05)。结论与哌拉西林舒巴坦钠比较,莫西沙星对社区获得性肺炎进行治疗,疗效显著,并且患者症状、体征恢复较快,是治疗获得性肺炎的良好选择。
Objective To compare the clinical efficacy of moxifloxacin and piperacillin-sulbactam sodium in the treatment of community-acquired pneumonia. Methods From March 2010 to March 2011, 98 cases of community-acquired pneumonia were randomly divided into two groups: 49 cases in group A were treated with moxifloxacin, and 49 cases in group B were treated with piperacillin-sulbactam sodium Clinical efficacy of both groups and the main symptoms and signs recovery. Results The total effective rate and bacterial clearance in group A were significantly higher than those in group B (P <0.05). A group of cough disappeared, body temperature returned to normal, blood returned to normal and significant absorption of chest imaging was significantly shorter than the B group (P <0.05). Conclusion Compared with piperacillin and sulbactam sodium, moxifloxacin is effective in the treatment of community-acquired pneumonia. The curative effect is significant, and the symptoms and signs of patients recover quickly.